ARVN
Price
$7.53
Change
+$0.61 (+8.82%)
Updated
Jun 6 closing price
Capitalization
505.1M
53 days until earnings call
ATXS
Price
$5.99
Change
+$0.77 (+14.75%)
Updated
Jun 6 closing price
Capitalization
294.59M
64 days until earnings call
Interact to see
Advertisement

ARVN vs ATXS

Header iconARVN vs ATXS Comparison
Open Charts ARVN vs ATXSBanner chart's image
Arvinas
Price$7.53
Change+$0.61 (+8.82%)
Volume$2.76M
Capitalization505.1M
Astria Therapeutics
Price$5.99
Change+$0.77 (+14.75%)
Volume$664.91K
Capitalization294.59M
ARVN vs ATXS Comparison Chart
Loading...
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARVN vs. ATXS commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a StrongBuy and ATXS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (ARVN: $7.28 vs. ATXS: $4.37)
Brand notoriety: ARVN and ATXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 139% vs. ATXS: 102%
Market capitalization -- ARVN: $505.1M vs. ATXS: $294.59M
ARVN [@Biotechnology] is valued at $505.1M. ATXS’s [@Biotechnology] market capitalization is $294.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 1 FA rating(s) are green whileATXS’s FA Score has 0 green FA rating(s).

  • ARVN’s FA Score: 1 green, 4 red.
  • ATXS’s FA Score: 0 green, 5 red.
According to our system of comparison, ARVN is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 5 TA indicator(s) are bullish while ATXS’s TA Score has 5 bullish TA indicator(s).

  • ARVN’s TA Score: 5 bullish, 3 bearish.
  • ATXS’s TA Score: 5 bullish, 1 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than ARVN.

Price Growth

ARVN (@Biotechnology) experienced а +16.56% price change this week, while ATXS (@Biotechnology) price change was +11.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

ARVN is expected to report earnings on Jul 31, 2025.

ATXS is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARVN($505M) has a higher market cap than ATXS($295M). ATXS YTD gains are higher at: -51.119 vs. ARVN (-61.998). ATXS has higher annual earnings (EBITDA): -111.56M vs. ARVN (-243.6M). ARVN has more cash in the bank: 1.04B vs. ATXS (328M). ATXS has less debt than ARVN: ATXS (5.35M) vs ARVN (9.7M). ARVN has higher revenues than ATXS: ARVN (263M) vs ATXS (0).
ARVNATXSARVN / ATXS
Capitalization505M295M171%
EBITDA-243.6M-111.56M218%
Gain YTD-61.998-51.119121%
P/E RatioN/AN/A-
Revenue263M0-
Total Cash1.04B328M317%
Total Debt9.7M5.35M181%
FUNDAMENTALS RATINGS
ARVN vs ATXS: Fundamental Ratings
ARVN
ATXS
OUTLOOK RATING
1..100
722
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
9693
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARVN's Valuation (17) in the Biotechnology industry is somewhat better than the same rating for ATXS (58). This means that ARVN’s stock grew somewhat faster than ATXS’s over the last 12 months.

ARVN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATXS (100). This means that ARVN’s stock grew similarly to ATXS’s over the last 12 months.

ARVN's SMR Rating (95) in the Biotechnology industry is in the same range as ATXS (97). This means that ARVN’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (93) in the Biotechnology industry is in the same range as ARVN (96). This means that ATXS’s stock grew similarly to ARVN’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ARVN (100). This means that ATXS’s stock grew similarly to ARVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARVNATXS
RSI
ODDS (%)
Bullish Trend 12 days ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 12 days ago
89%
Bullish Trend 12 days ago
81%
Momentum
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 12 days ago
73%
MACD
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 12 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend 12 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
86%
Bearish Trend 12 days ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 12 days ago
80%
Declines
ODDS (%)
Bearish Trend 26 days ago
82%
Bearish Trend about 1 month ago
90%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
86%
N/A
Aroon
ODDS (%)
Bullish Trend 12 days ago
62%
Bullish Trend 12 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with ATXS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
+8.89%
ATXS - ARVN
39%
Loosely correlated
+6.85%
ERAS - ARVN
39%
Loosely correlated
+1.85%
ABOS - ARVN
38%
Loosely correlated
N/A
TECH - ARVN
37%
Loosely correlated
-1.56%
CRBU - ARVN
37%
Loosely correlated
+2.75%
More

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with DNLI. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+6.85%
DNLI - ATXS
56%
Loosely correlated
-1.29%
KYMR - ATXS
56%
Loosely correlated
+2.35%
XENE - ATXS
55%
Loosely correlated
-3.29%
TRDA - ATXS
54%
Loosely correlated
+0.91%
CRNX - ATXS
54%
Loosely correlated
+1.39%
More